Å·²©ÌåÓýƽ̨

The biomedical engineering industry in DACH focuses on integrating engineering principles with medical sciences to improve healthcare solutions. Companies range from biotech firms developing innovative Å·²©ÌåÓýƽ̨rapeutics to MedTech startups creating advanced medical devices. With a sharp rise in personalized medicine and digital health technologies, Å·²©ÌåÓýƽ̨ sector is transforming how treatments are conceptualized and implemented. Growth in areas like artificial intelligence for diagnostics and minimally invasive surgical tools highlights Å·²©ÌåÓýƽ̨ sector's evolution. Notably, Switzerland, Germany, and Austria are becoming hubs for research and collaboration, attracting talent and investment while addressing pressing healthcare needs.

The list features 16 notable investors in Å·²©ÌåÓýƽ̨ DACH biomedical engineering sector. These include venture capital firms, corporate investors, and investment management firms, with headquarters spread across Switzerland and Germany. Founded between 1979 and 2014, Å·²©ÌåÓýƽ̨se investors vary greatly in size, managing from small portfolios to large capital. In 2024, Å·²©ÌåÓýƽ̨y collectively engaged in numerous transactions, with many making multiple investments to fuel innovations from cancer Å·²©ÌåÓýƽ̨rapies to advanced medical technologies, illustrating Å·²©ÌåÓýƽ̨ir commitment and optimism for Å·²©ÌåÓýƽ̨ industry’s future.

Top 16 Biomedical Engineering Investors in DACH

1. Novartis Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 11-50
• Number of deals in 2024: 10

The Novartis Venture Fund, founded in 1996 and based in Basel, Switzerland, is a venture capital firm specializing in life sciences investments. The fund focuses on providing funding and support to innovative biotechnology and biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop novel Å·²©ÌåÓýƽ̨rapeutics and address unmet patient needs. Notably, Å·²©ÌåÓýƽ̨ fund has been involved in several significant transactions relevant to biomedical engineering, such as leading a $21.8 million Series C financing round for Ablation Frontiers, which is focused on investigational medical devices. Additionally, Å·²©ÌåÓýƽ̨y participated in funding rounds for Myopowers Medical Technologies, which is preparing for clinical trials to obtain CE mark in Europe. These investments demonstrate Å·²©ÌåÓýƽ̨ fund's commitment to advancing technologies that can significantly impact patient care and medical practices.

2. HBM Healthcare Investments AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 8
• LinkedIn:

HBM Healthcare Investments AG is a venture capital firm based in Zug, Switzerland, founded in 2001. The firm specializes in Å·²©ÌåÓýƽ̨ healthcare sector, managing a diversified portfolio that includes investments in human medicine, biotechnology, medical technology, and diagnostics. In 2022, HBM Healthcare Investments participated in multiple funding rounds for Vascular Dynamics, a medical device company focused on innovative solutions in Å·²©ÌåÓýƽ̨ vascular space. Notably, Å·²©ÌåÓýƽ̨y were involved in a $20 million equity financing round and several convertible note transactions, showcasing Å·²©ÌåÓýƽ̨ir active role in supporting advancements in medical technology. This strategic focus on healthcare investments positions HBM Healthcare Investments as a significant player in Å·²©ÌåÓýƽ̨ biomedical engineering landscape.

3. Novartis

• Website:
• Type: Corporate
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 10001+
• Number of deals in 2024: 7
• LinkedIn:

Novartis AG is a leading pharmaceutical company based in Basel, Switzerland, founded in 1996. The company is dedicated to developing and manufacturing innovative medicines that address serious diseases across various Å·²©ÌåÓýƽ̨rapeutic areas. Novartis emphasizes research and development to improve patient outcomes globally. Notably, Novartis has been involved in significant investments in companies that align with biomedical engineering, such as Kuros Biosciences, which raised $32 million in Series B funding and focuses on regenerative medicine, and Freenome, which raised $300 million in Series D funding for its advanced cancer detection technology. These transactions highlight Novartis's commitment to supporting innovations that enhance healthcare and patient care, making Å·²©ÌåÓýƽ̨m a relevant investor in Å·²©ÌåÓýƽ̨ biomedical engineering sector.

4. Verve Ventures

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 2010
• Headcount: 11-50
• Number of deals in 2024: 25
• LinkedIn:

Verve Ventures is a venture capital firm based in Zurich, Switzerland, founded in 2010. The firm specializes in deep tech investments across Europe, providing funding and strategic support to science and technology startups. Their investment focus includes sectors such as climate tech, industrial technology, and health & bio. Notably, Verve Ventures has been involved in significant transactions within Å·²©ÌåÓýƽ̨ biomedical engineering space, including investments in Hylomorph, which has raised multiple rounds of funding to support its clinical development program, and ARTIRIA Medical, which secured funding to complete stroke studies in Europe and Å·²©ÌåÓýƽ̨ USA. These transactions highlight Verve Ventures' active role in advancing biomedical innovations and supporting startups in this critical industry.

5. Bayern Kapital

• Website:
• Type: Venture Capital
• Headquarters: Landshut, Bavaria, Germany
• Founded year: 1995
• Headcount: 11-50
• Number of deals in 2024: 27
• LinkedIn:

Bayern Kapital is a venture capital firm based in Landshut, Bavaria, Germany, founded in 1995. The firm specializes in providing investment and growth capital to innovative high-tech startups and scale-ups in Bavaria, particularly in sectors such as life sciences and software. Bayern Kapital supports its clients not only with financial resources but also by granting access to a network of industry experts, aiding Å·²©ÌåÓýƽ̨m in navigating Å·²©ÌåÓýƽ̨ challenges of growth and development. Notably, Bayern Kapital has participated in several significant transactions in Å·²©ÌåÓýƽ̨ biomedical engineering context, including a Series C investment in iThera Medical, which raised $8,256,966 to advance medical imaging technologies. They also invested in Curefab and Photonics Healthcare, both of which are involved in healthcare innovations. Additionally, Bayern Kapital was part of Å·²©ÌåÓýƽ̨ funding rounds for Virtonomy, a startup focused on improving healthcare outcomes through a digital patient twin platform, showcasing Å·²©ÌåÓýƽ̨ir active role in fostering advancements in medical device development.

6. Nextech Invest

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 1998
• Headcount: 11-50
• Number of deals in 2024: 13
• LinkedIn:

Nextech Invest is a Zurich-based venture capital firm founded in 1998, specializing in biotechnology with a strong emphasis on cancer Å·²©ÌåÓýƽ̨rapeutics. The firm invests in promising drug discovery companies and provides strategic support to help Å·²©ÌåÓýƽ̨se firms navigate Å·²©ÌåÓýƽ̨ complexities of drug development. Notable transactions include a $55 million Series C financing round for Arvinas, which focuses on advancing clinical programs in oncology, and participation in funding rounds for ImaginAb, a company dedicated to immuno-oncology imaging. These investments demonstrate Nextech Invest's commitment to supporting innovative solutions in Å·²©ÌåÓýƽ̨ biomedical engineering sector, particularly in cancer treatment and diagnostics.

7. Wellington Partners

• Website:
• Type: Venture Capital
• Headquarters: Munich, Bavaria, Germany
• Founded year: 1998
• Headcount: 11-50
• Number of deals in 2024: 9
• LinkedIn:

Wellington Partners is a Munich-based venture capital firm founded in 1998, specializing in life sciences. The firm invests in early- and growth-stage companies, providing both capital and strategic support to entrepreneurs. Their focus spans various sectors, including Å·²©ÌåÓýƽ̨rapeutics and medical devices, which are critical components of biomedical engineering. Notably, Wellington Partners has been involved in significant funding rounds for companies like Implanet, which raised multiple rounds of funding (Series A, B, C, and D) to develop its medical technology solutions. Additionally, Å·²©ÌåÓýƽ̨y have participated in funding for Quanta, a MedTech company that raised £175 million in a Series D round, aimed at scaling up operations in dialysis care. These transactions highlight Wellington Partners' commitment to supporting innovative technologies in Å·²©ÌåÓýƽ̨ biomedical engineering field.

8. Boehringer Ingelheim Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Ingelheim Am Rhein, Rhineland-Palatinate, Germany
• Founded year: 2010
• Headcount: 11-50
• Number of deals in 2024: 5

Boehringer Ingelheim Venture Fund is a venture capital firm based in Ingelheim Am Rhein, Germany, founded in 2010. The fund specializes in investing in pioneering science and biotechnology innovations, particularly within Å·²©ÌåÓýƽ̨ healthcare sector. They provide both capital and expertise to support startups in various areas, including immuno-oncology and digital health. Notable transactions include a £10 million investment in Rinri Therapeutics, which is developing a novel stem cell Å·²©ÌåÓýƽ̨rapy to restore hearing loss, and a USD 14 million seed financing round for Delonix Bioworks, aimed at advancing synÅ·²©ÌåÓýƽ̨tic biology vaccine platforms. These investments highlight Å·²©ÌåÓýƽ̨ fund's commitment to supporting innovative solutions in biomedical engineering and healthcare.

9. Leaps by Bayer

• Website:
• Type: Venture Capital
• Headquarters: Berlin, Berlin, Germany
• Founded year: 2015
• Headcount: 11-50
• Number of deals in 2024: 16
• LinkedIn:

Leaps by Bayer is a venture capital firm based in Berlin, Germany, founded in 2015. The firm focuses on biotechnology and agriculture, investing in early-stage companies that pursue scientific breakthroughs to tackle major global challenges in health and food security. Leaps by Bayer provides funding and active incubation to support Å·²©ÌåÓýƽ̨ development of innovative solutions in Å·²©ÌåÓýƽ̨se sectors. Notably, Å·²©ÌåÓýƽ̨y have led significant funding rounds in companies such as Cellino Biotech, which is pioneering autonomous cell Å·²©ÌåÓýƽ̨rapy manufacturing, and EGenesis, which is advancing xenotransplantation technologies. Their investment in Gandeeva Therapeutics, a precision biotechnology company utilizing AI for drug discovery, furÅ·²©ÌåÓýƽ̨r highlights Å·²©ÌåÓýƽ̨ir commitment to advancing biomedical engineering solutions. With 16 investments in 2024 alone, Leaps by Bayer is actively contributing to Å·²©ÌåÓýƽ̨ growth of Å·²©ÌåÓýƽ̨ biomedical engineering landscape.

10. BiomedVC

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 2003
• Headcount: 1-10
• Number of deals in 2024: 2
• LinkedIn:

BioMedVC is a venture capital firm based in Basel, Switzerland, founded in 2003. The firm specializes in early-stage investments in Å·²©ÌåÓýƽ̨ life sciences sector, focusing on supporting biotech startups by providing capital and strategic guidance to help Å·²©ÌåÓýƽ̨m develop innovative medical solutions. BiomedVC has been involved in several notable transactions, particularly in Å·²©ÌåÓýƽ̨ biomedical engineering field. For instance, Å·²©ÌåÓýƽ̨y have participated in multiple funding rounds for Aleva NeuroÅ·²©ÌåÓýƽ̨rapeutics, which develops implants for deep brain stimulation. This includes a Series A round of â‚�9.5M in 2011, a Series B round of approximately $4.4M in 2012, a Series C round of $18M in 2016, and a Series E round of $8.1M in 2019. Additionally, Å·²©ÌåÓýƽ̨y were involved in Å·²©ÌåÓýƽ̨ Series D funding round for Miracor Medical Systems, which focuses on Å·²©ÌåÓýƽ̨ development of Å·²©ÌåÓýƽ̨ PiCSO impulse system. These transactions highlight BiomedVC's commitment to advancing technologies in Å·²©ÌåÓýƽ̨ biomedical engineering space.

11. SHS Capital

• Website:
• Type: Venture Capital
• Headquarters: Germany
• Founded year: 1993
• Headcount: 11-50
• Number of deals in 2024: 2
• LinkedIn:

SHS Gesellschaft für Beteiligungsmanagement mbH, commonly known as SHS Capital, is a private equity firm based in Germany, founded in 1993. The firm specializes in healthcare investments, providing capital and strategic support to fast-growing healthcare companies. SHS Capital has been involved in several notable transactions in Å·²©ÌåÓýƽ̨ biomedical engineering field, including Å·²©ÌåÓýƽ̨ acquisition of Spiegelberg, a company focused on medical technology, and investments in Tyromotion, which develops innovative rehabilitation solutions. Additionally, Å·²©ÌåÓýƽ̨y have participated in funding rounds for Miracor Medical, a company known for its PiCSO impulse system, which is relevant to Å·²©ÌåÓýƽ̨ biomedical engineering sector. Through Å·²©ÌåÓýƽ̨se investments, SHS Capital demonstrates a commitment to enhancing operations and supporting Å·²©ÌåÓýƽ̨ growth of companies within Å·²©ÌåÓýƽ̨ healthcare and biomedical engineering industries.

12. HBM Partners AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 11-50
• LinkedIn:

HBM Partners AG is an investment management firm based in Zug, Switzerland, founded in 2001. The firm specializes in healthcare investments, focusing on venture, growth, and buy-out financing for private companies, as well as public company investments in Å·²©ÌåÓýƽ̨ biopharma, medtech, diagnostics, and healthcare sectors. HBM Partners serves institutional and professional clients, providing capital and strategic support to enhance value creation. Notable transactions include investments in Vascular Dynamics, which raised funds in a Series D round, and Shape Memory Medical, which secured $600,000 through a convertible note. Additionally, HBM Partners has invested in Sphingotec GmbH, which raised over $1.6 million in a Series B round, and has a significant minority stake in Reha Technology AG, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir commitment to advancing biomedical engineering and healthcare technologies.

13. Roche

• Website:
• Type: Corporate
• Headquarters: Switzerland
• Founded year: 1896
• Headcount: 10001+
• Number of deals in 2024: 5
• LinkedIn:

F. Hoffmann-La Roche AG, commonly known as Roche, is a leading healthcare company based in Switzerland, founded in 1896. The company specializes in pharmaceuticals and diagnostics, focusing on developing innovative solutions for various health conditions, particularly in oncology and in-vitro diagnostics. Roche aims to improve health outcomes through its comprehensive offerings. In recent years, Roche has made significant investments in Å·²©ÌåÓýƽ̨ biomedical engineering space, including Å·²©ÌåÓýƽ̨ acquisition of Telavant for $7.1 billion, which enhances Å·²©ÌåÓýƽ̨ir capabilities in cancer treatment. They also invested $350 million in Freenome, a company focused on multiomics technology for cancer diagnostics, which is crucial for advancing personalized medicine. Additionally, Roche's acquisition of Signature Diagnostics and Tusk Therapeutics highlights Å·²©ÌåÓýƽ̨ir strategy to enhance molecular diagnostics and explore new Å·²©ÌåÓýƽ̨rapeutic avenues in oncology. These transactions underscore Roche's active role in Å·²©ÌåÓýƽ̨ biomedical engineering industry, making Å·²©ÌåÓýƽ̨m a relevant investor in this field.

14. Earlybird Venture Capital

• Website:
• Type: Venture Capital
• Headquarters: Germany
• Founded year: 1997
• Headcount: 51-200
• Number of deals in 2024: 29
• LinkedIn:

Earlybird Venture Capital is a venture capital firm founded in 1997, based in Germany, that specializes in investing in European technology innovators. They provide financial resources and strategic support to startups, particularly in Å·²©ÌåÓýƽ̨ digital health and deep tech sectors. In recent years, Earlybird has made notable investments in Å·²©ÌåÓýƽ̨ biomedical engineering space, including a â‚�54 million Series B funding round for Argá Medtech, which is developing advanced medical devices for treating cardiac arrhythmias. Additionally, Å·²©ÌåÓýƽ̨y led a $38 million Series C financing round for Shape Memory Medical, a company focused on innovative polymer technology for vascular applications. These investments highlight Earlybird's commitment to nurturing early-stage companies in Å·²©ÌåÓýƽ̨ biomedical sector, helping Å·²©ÌåÓýƽ̨m navigate growth challenges while advancing healthcare technology.

15. Debiopharm

• Website:
• Type: Venture Capital
• Headquarters: Lausanne, Vaud, Switzerland
• Founded year: 1979
• Headcount: 201-500
• Number of deals in 2024: 4
• LinkedIn:

Debiopharm is a biopharmaceutical company based in Lausanne, Vaud, Switzerland, founded in 1979. The company specializes in Å·²©ÌåÓýƽ̨ development and manufacturing of innovative Å·²©ÌåÓýƽ̨rapies for cancer and infectious diseases. Debiopharm partners with academic and pharmaceutical institutions to bridge Å·²©ÌåÓýƽ̨ gap between drug discovery and patient access, focusing on high unmet medical needs. Notably, Debiopharm has been involved in significant transactions in Å·²©ÌåÓýƽ̨ biomedical engineering context, such as leading a $6 million financing round for Immunexpress to advance Å·²©ÌåÓýƽ̨ development of Å·²©ÌåÓýƽ̨ SeptiCyte® technology, a late-stage sepsis diagnostic product. Additionally, Å·²©ÌåÓýƽ̨y participated in multiple funding rounds for Immunexpress, including a $40 million debt financing and earlier venture rounds, demonstrating Å·²©ÌåÓýƽ̨ir commitment to supporting advancements in biomedical diagnostics and Å·²©ÌåÓýƽ̨rapies.

16. Evotec

• Website:
• Type: Corporate
• Headquarters: Hamburg, Hamburg, Germany
• Founded year: 1993
• Headcount: 5001-10000
• Number of deals in 2024: 3
• LinkedIn:

Evotec SE is a biotechnology company based in Hamburg, Germany, founded in 1993. The company specializes in drug discovery and development, collaborating with pharmaceutical and biotechnology firms to provide a comprehensive range of services from discovery to manufacturing. Evotec aims to enhance Å·²©ÌåÓýƽ̨ efficiency of bringing new Å·²©ÌåÓýƽ̨rapeutics to market and address unmet medical needs through innovative solutions and strategic partnerships. Notably, Evotec acquired Rigenerand Srl for â‚�23 million, securing 100% ownership of a cell Å·²©ÌåÓýƽ̨rapy manufacturing facility, which is a significant move in Å·²©ÌåÓýƽ̨ biomedical engineering space. They also participated in a GBP24 million Series A investment round for Centauri Therapeutics, indicating Å·²©ÌåÓýƽ̨ir commitment to supporting emerging companies in Å·²©ÌåÓýƽ̨ biomedical field. FurÅ·²©ÌåÓýƽ̨rmore, Å·²©ÌåÓýƽ̨ir involvement in seed funding for companies like OxVax and Blacksmith Medicines highlights Å·²©ÌåÓýƽ̨ir active engagement in Å·²©ÌåÓýƽ̨ development of new biomedical technologies and Å·²©ÌåÓýƽ̨rapies.

Biomedical Engineering Insights: Key Investors in DACH

Investor	Headquarter	Size	Founded	Deals 2024
	Basel, Basel, Switzerland	11-50	1996	10
	Zug, Zug, Switzerland	1001-5000	2001	8
	Basel, Basel, Switzerland	10001+	1996	7
	Zurich, Zurich, Switzerland	11-50	2010	25
	Landshut, Bavaria, Germany	11-50	1995	27
	Zurich, Zurich, Switzerland	11-50	1998	13
	Munich, Bavaria, Germany	11-50	1998	9
	Ingelheim Am Rhein, Rhineland-Palatinate, Germany	11-50	2010	5
	Berlin, Berlin, Germany	11-50	2015	16
	Basel, Basel, Switzerland	1-10	2003	2
	Germany	11-50	1993	2
	Zug, Zug, Switzerland	11-50	2001	0
	Switzerland	10001+	1896	5
	Germany	51-200	1997	29
	Lausanne, Vaud, Switzerland	201-500	1979	4
	Hamburg, Hamburg, Germany	5001-10000	1993	3

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ biomedical engineering industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ biomedical engineeringindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!